Micafungin Ratiopharm (Micafungin)

Micafungin is an echinocandin antifungal that targets invasive fungal infections.

• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves mucosal Candida infection of the esophagus.
• Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection in patients undergoing HSCT.

• Micafungin inhibits the enzyme responsible for synthesizing β‑(1,3)‑D‑glucan, an essential polysaccharide of the fungal cell wall. By blocking this pathway, the drug weakens cell wall integrity, causing osmotic instability and fungal cell lysis. The mechanism is selective for fungal cells, resulting in minimal impact on human host tissues.

Micafungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature.
• Nausea: mild to moderate feeling of sickness.
• Headache: occasional mild headache.
• Elevated liver enzymes: mild increase in ALT/AST.
• Infusion‑related reactions: erythema, flushing, or mild hypotension.

Serious or Rare Side Effects

• Hepatotoxicity: significant liver injury with marked enzyme elevation.
• Severe hypersensitivity: anaphylaxis or angioedema.
• Renal impairment: acute kidney injury.
• Severe neutropenia: marked reduction in neutrophil count.

When using Micafungin, clinicians should consider several safety and handling precautions.

• Liver function monitoring: assess baseline and periodic ALT/AST levels.
• Renal function assessment: evaluate serum creatinine before and during therapy.
• Drug interactions: review concomitant medications that affect hepatic metabolism.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited.
• Patient hypersensitivity: discontinue if signs of severe allergic reaction appear.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Cyclosporine: increased micafungin exposure may raise toxicity risk.
• Rifampin: strong enzyme induction may reduce micafungin concentrations.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): potential additive hepatotoxicity.
• Warfarin: possible alteration of anticoagulant effect.
• Statins (e.g., simvastatin): monitor for increased muscle toxicity.